Teratogenicity of bromocryptine in pregnant rats.
The teratogenicity of bromocryptine (CB-154, Sandoz, Basel) was studied in three groups of pregnant rats which received 0.625 mg/kg/day, 1.25 mg/kg/day, and 2.5 mg/kg/day bromocryptine, respectively, i.m. and in a control group of pregnant rats which received the solvent only. There was no significant difference in the birth rate, fetal resorption rate, male/female ratio and malformation rate between the four groups. There was a significant elevation of the average fetal and placental weights between the experimental and the control fetuses. Bromocryptine does cross the placental barrier and in our study might act as growth promoting factor.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000818:Animals; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005333:Fetus / Q000187:drug effects*; D011247:Pregnancy; D051381:Rats; D011919:Rats, Inbred Strains
D001971:Bromocriptine